Goldman Sachs upgraded Johnson & Johnson (JNJ) from Neutral to Buy, citing underappreciated Innovative Medicine business and upcoming product cycles.
Latest Ratings for JNJ
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 2022 | Raymond James | Maintains | Outperform | |
| Jan 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Dec 2021 | Goldman Sachs | Initiates Coverage On | Neutral |
